Navigation Links
Launch of Ipsen's Decapeptyl(R) 6-Month Formulation (LP 22.5 mg) in France for the Treatment of Locally Advanced or Metastatic Hormone-Dependent Prostate Cancer
Date:2/4/2010

PARIS and LAUSANNE, Switzerland, February 4 /PRNewswire/ -- Ipsen (Euronext: FR0010259150; IPN), an innovation-driven global specialty pharmaceutical group and Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, announce the launch by Ipsen in France of Decapeptyl(R) LP 22.5 mg 6-month sustained-release formulation for the treatment of locally advanced or metastatic hormone-dependent prostate cancer. Other launches are planned shortly, notably in Germany and Portugal.

The marketing authorisation (MA) to this 6-month sustained-release formulation of Decapeptyl(R) (triptorelin embonate[1] 22.5 mg) was granted on 10 November 2009 by the French regulatory authorities (Agence Francaise de Securite Sanitaire des Produits de Sante, AFSSAPS) for the treatment of locally advanced and metastatic hormone-dependent prostate cancer. France was the first country to approve Decapeptyl(R) LP 22.5 mg in the context of a Decentralised Procedure in Europe. The reimbursement rate by Social Security and price setting decision have been published in the Journal Officiel of 3 February 2010, i.e. less than three months after MA was granted.

Decapeptyl(R) LP 22.5 mg is the new sustained-release 6-month formulation of a gonatropin- releasing hormone (GnRH) agonist analogue developed by Debiopharm Group. Debiopharm has licensed the marketing rights to Ipsen for all territories where Ipsen currently commercialises triptorelin.

On '/>"/>

SOURCE Debiopharm Group
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. BD Launches Be a Flu Fighter Campaign to Promote Influenza Awareness and Prevention in Schools, Hospitals and Laboratories
2. Kantar Health and ImpactRx Launch CancerMPact Monthly Drugs and Regimens for Oncology Business Decisions
3. Elekta Launches New Web Site for Global Health Care Community
4. WellWorld Science(R) Announces U.S. Launch of Livea(R),a Safe and Natural Appetite Control Supplement
5. Healthpoint Launches Collagenase SANTYL(R) Ointment in Canada
6. BioCrysts Partner Shionogi Launches Peramivir In Japan Under The Name RAPIACTA
7. American Imaging Management Launches New Patient Safety Program Podcasts
8. Sinovac Announces Plan to Launch Offering of Common Shares
9. VisEn Launches New Cat B 680 FAST(TM) Fluorescence Molecular Imaging Agent
10. Ambry Genetics Announces Launch of Their StemArray(TM) Product and Services for High Resolution Characterization of Human Stem Cells
11. Sagent Pharmaceuticals Launches Pamidronate Disodium Injection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... Elekta (NSE:EKTAb) and Royal Philips ... Foundation Trust ( Manchester, UK ), a ... is to develop the clinical value of an integrated ... a system would, in principle, improve the practice of ... "The Christie was an essential participant in the ...
(Date:7/22/2014)... 2014 Sanofi Pasteur, the vaccines division of Sanofi ... that the first lots of Fluzone ® (Influenza Vaccine) ... by the U.S. Food and Drug Administration (FDA) for distribution. ... first of at least 65 million doses of seasonal influenza ... U.S. health care providers and pharmacies in August. ...
(Date:7/22/2014)... SAN DIEGO , July 22, 2014  Halozyme ... that it has resumed enrollment and dosing of patients ... PEGPH20 in patients with pancreatic cancer under the revised ... PEGPH20 is an investigational PEGylated form of Halozyme,s proprietary ... of tumors that accumulate hyaluronan. "Our ...
Breaking Medicine Technology:The Christie Hospital joins Elekta and Philips research consortium to develop MRI-guided radiation therapy system for cancer treatment 2The Christie Hospital joins Elekta and Philips research consortium to develop MRI-guided radiation therapy system for cancer treatment 3The Christie Hospital joins Elekta and Philips research consortium to develop MRI-guided radiation therapy system for cancer treatment 4Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 2Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 3Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 4Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 5Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 6Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 7Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer 2Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer 3
... ALL Study Group Presented Data at the 14th Congress ... in Patients with Minimal Residual Disease , , ... MITI ), a biopharmaceutical company developing novel, proprietary antibodies ... announced that the German Multicenter ALL Study Group (GMALL) ...
... 2 data sets to be released-- , ... clinical trials in patients with blepharospasm and cervical dystonia -- ... -- were presented at the Movement Disorder Society (MDS) 13th ... by Merz Pharmaceuticals, which plans to file a Biologic License ...
Cached Medicine Technology:Micromet's Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients 2Micromet's Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients 3Micromet's Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients 4Micromet's Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients 5Merz Pharmaceuticals Announces Results of Clinical Trials with NT-201(Botulinum neurotoxin type A free from complexing proteins) at Annual Movement Disorders Society Meeting 2Merz Pharmaceuticals Announces Results of Clinical Trials with NT-201(Botulinum neurotoxin type A free from complexing proteins) at Annual Movement Disorders Society Meeting 3Merz Pharmaceuticals Announces Results of Clinical Trials with NT-201(Botulinum neurotoxin type A free from complexing proteins) at Annual Movement Disorders Society Meeting 4
(Date:7/23/2014)... Hemodialysis equipment is the most widely used ... acute or chronic renal failure. , The Chinese hemodialysis ... European, American and Japanese enterprises. In 2013, the import ... growing demand for hemodialysis equipment in China, its import ... in 2009-2013. Germany, Sweden and Japan as the main ...
(Date:7/23/2014)... month of July, LunaDress, a well-known wedding dress manufacturer and ... hosting a couple of promotions on its website. Recently, the ... wedding dresses for the UK market . The fresh range ... are now offered with huge discounts, from 20 to 70 ... suppliers, LunaDress is always making full efforts to offer classy ...
(Date:7/23/2014)... 23, 2014 World Gardens Café, the ... healthy gourmet cuisine, received rave reviews last week when ... Mixer. Mixer attendees were amazed that healthy food could ... World Gardens Café, the premier provider of delicious and ... booth at Dave Linden’s LA’s Largest Mixer. Attendees who ...
(Date:7/23/2014)... 2014 Sanuvox has produced a ... of the company’s latest system designed for hospital ... System uses a primary and secondary unit to ... ‘C’ energy controlling (6 log reduction) drug-resistant microorganisms ... than 10 minutes in a standard patient hospital ...
(Date:7/23/2014)... Low enrollment and higher-than-expected administrative costs ... up with alternative means to becoming self-sustaining. Industry ... accomplish this in the July 17 issue of ... , “We never expected the operating budgets would ... an attorney at the law firm Venable LLP ...
Breaking Medicine News(10 mins):Health News:China Hemodialysis Equipment Market (Import & Export) Report 2013-2016 Now Available at ChinaMarketResearchReports.com 2Health News:China Hemodialysis Equipment Market (Import & Export) Report 2013-2016 Now Available at ChinaMarketResearchReports.com 3Health News:China Hemodialysis Equipment Market (Import & Export) Report 2013-2016 Now Available at ChinaMarketResearchReports.com 4Health News:LunaDress Continues To Enrich Product Line By Offering Short Summer Beach Wedding Dresses 2Health News:Healthy Food Gets Rave Reviews at LA’s Largest Mixer 2Health News:Sanuvox Produces ASEPTIX² Movie Showcasing the Feature Benefits of the Company’s Latest Flagship Hospital Surface Disinfection System 2Health News:Industry Observers Tell AIS They Predict Changes to Exchange User Fees, Platforms 2Health News:Industry Observers Tell AIS They Predict Changes to Exchange User Fees, Platforms 3
... from the University of North Carolina at Chapel Hill suggests that ... morning or later in the afternoon can influence the onset ... exposure to UV radiation in the morning increased the risk of ... Although mice and humans both reside on a 24-hour day, the ...
... Rockville, MD -- Physical activity may be what the ... developing glaucoma. According to a recently published scientific paper, ... long-term beneficial impact on low ocular perfusion pressure (OPP), ... the Investigative Ophthalmology & Visual Science journal ...
... LANSING, Mich. -- Despite the fact mental health problems ... combined, about two-thirds of mental health patients are cared ... Additionally, even larger numbers of other patients regularly ... A new five-year, $1 million grant allows Michigan State ...
... related macular degeneration (AMD) is the leading cause of ... identified several relatively common genetic variants which together predict ... number of persons without the disease also have these ... able to clearly show a specific rare mutation called ...
... study published today in the journal Nature Genetics ... Lieb, PhD, present experiments supporting a longstanding hypothesis that ... of the X chromosome. The finding provides clarity to ... with more information to interpret experiments involving genetic measurements ...
... FESC, from the University of Padua, Italy, explains, "To ... from all the different imaging modalities, not just Echo. ... is that we want to become more patient oriented, ... the most appropriate technology to address individual clinical questions." ...
Cached Medicine News:Health News:Morning UV exposure may be less damaging to the skin 2Health News:Physical fitness could have a positive effect on eye health 2Health News:Residency program focuses on overlooked mental health needs 2Health News:Researchers ID genetic mutation associated with high risk of age-related macular degeneration 2Health News:Study confirms males and females have at least 1 thing in common: Upregulating X 2Health News:Congress alert: EUROECHO and Other Imaging Modalities: New patient emphasis 2Health News:Congress alert: EUROECHO and Other Imaging Modalities: New patient emphasis 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: